Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis
Stopped The risk-benefit ratio for patients has changed since we initiated the study, and that the study in its current form cannot be justified
Conditions
Interventions
- DRUG: Otelixizumab
- DRUG: Matching placebo
Sponsor
GlaxoSmithKline